Overview

Prolonged Adjuvant Temozolomide vs "Stop & Go" in Glioblastoma Patients

Status:
Unknown status
Trial end date:
2012-01-01
Target enrollment:
Participant gender:
Summary
This study will test the hypothesis that prolonged adjuvant Temozolomide (TMZ) may delay relapses in patients with glioblastoma compared to the standard care consisting in observation with brain MRI every 3 months and rechallenging with TMZ at relapse (Stop and Go arm).
Phase:
Phase 2
Details
Lead Sponsor:
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Treatments:
Dacarbazine
Temozolomide